Company Profile

ABBISKO-B

2256 Biotechnology
Description

Abbisko Cayman Limited, an investment holding company, engages in the research and development of pharmaceutical products in the People's Republic of China. The company develops Pimicotinib, which is in Phase III clinical trial for the treatment of tenosynovial giant cell tumor; Irpagratinib for the treatment of hepatocellular carcinoma; ABSK043 that is in Phase I clinical trial for the treatment of non-small cells lung cancer; and ABSK061 for the treatment of solid tumors. It also develops Fexagratinib, which is in Phase II clinical trial for the treatment of urothelial carcinoma; ABSK121, a small molecule FGFR inhibitor that targets both wild-type and mutations of FGFR1-3; ABSK112, an EGFR Exon20ins inhibitor with selectivity over wild-type EGFR and brain-penetration activity; Mavorixafor, an orally bioavailable CXCR4 modulator; and ABSK051, a small molecule CD73 inhibitor for the treatment of various tumor types, such as lung and pancreatic cancer. In addition, the company develops ABSK012, which is in Phase I clinical trial for treatment of soft tissue sarcoma; ABK131, a selective MTA-cooperative and brain-penetrant PRMT5 inhibitor; ABK3376, which is in Phase I clinical trial for the treatment of NSCLC harboring the EGFR-C797S mutation; and ABSK141, an orally bioavailable small-molecule KRAS-G12D inhibitor. Abbisko Cayman Limited was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.

Reports

This company has 4 ESG reports available.

ESG Performance Overview

Select a KPI indicator to view performance trend

KPI Indicators

A1.1 Emission Types and Data
3 Data Points
Indicator Data Points Actions
SOₓ Emissions 1
NOₓ Emissions 1
Airborne Particulate Matter (PM) Emissions 1
A1.2 Direct (Scope 1) and Indirect (Scope 2) GHG Emissions
46 Data Points
Indicator Data Points Actions
Scope 3 GHG Emissions (Business Travel) 1
Total GHG Emissions Intensity (By Employee) 9
Total GHG Emissions Intensity (By Area) 9
Total GHG Emissions 9
Direct GHG Emissions (Scope 1) 9
Indirect Energy Emissions (Scope 2) 9
A1.3 Hazardous Waste
12 Data Points
Indicator Data Points Actions
Total Hazardous Waste Intensity (By Employee) 3
Total Hazardous Waste 9
A1.4 Non-Hazardous Waste
26 Data Points
Indicator Data Points Actions
Paper Waste 11
Non-Hazardous Waste (Office Waste) 6
Total Non-Hazardous Waste Intensity (By Employee) 9

A2.1 Energy Consumption
36 Data Points
Indicator Data Points Actions
Purchased Electricity Intensity (By Employee) 2
Total Electricity Consumption Intensity (By Employee) 1
Purchased Electricity Intensity (By Area) 5
Total Electricity Consumption Intensity (By Area) 1
Gasoline Consumption 15
Total Indirect Energy Consumption 1
Total Purchased Energy 1
Purchased Electricity 9
Grid Electricity Consumption 1
A2.2 Water Consumption
12 Data Points
Indicator Data Points Actions
Total Wastewater Discharge 2
Water Consumption 9
Water Consumption Intensity (By Revenue) 1
A2.5 Total Packaging Material Used
1 Data Points
Indicator Data Points Actions
Packaging Materials Consumed 1

B1.1 Amount and Distribution of Workforce
136 Data Points
Indicator Data Points Actions
Number of Total Employees 9
Number of Male Employees 9
Number of Female Employees 9
Percentage of Male Employees 3
Percentage of Female Employees 5
Number of Full-time Employees 8
Percentage of Full-time Employees 1
Number of Employees Aged Below 30 9
Number of Employees Aged 30-50 9
Number of Employees Aged Above 50 9
Percentage of Employees Aged Below 30 3
Percentage of Employees Aged 30-50 3
Percentage of Employees Aged Above 50 3
Number of Employees in Mainland China 8
Number of Employees in Overseas 8
Number of Employees in East China 1
Number of Employees in Central China 1
Number of Employees in Northwest China 1
Percentage of Employees in Mainland China 2
Percentage of Employees in Overseas 2
Percentage of Employees in East China 1
Percentage of Employees in Central China 1
Percentage of Employees in Northwest China 1
Number of Senior Management Employees 9
Number of Middle Management Employees 9
Number of Junior Management Employees 3
Percentage of Senior Management Employees 3
Percentage of Middle Management Employees 3
Percentage of Junior Management Employees 3
B1.2 Employee Turnover Rate
64 Data Points
Indicator Data Points Actions
Turnover Rate of Female Employees 9
Turnover Rate of Male Employees 9
Turnover Rate of Employees Aged Below 30 9
Turnover Rate of Employees Aged 30-50 9
Turnover Rate of Employees Aged Above 50 9
Turnover Rate of Employees in Mainland China 9
Turnover Rate of Total Employees 9
Turnover Rate of Employees in Overseas 1

B2.1 Number and Rate of Work-related Fatalities
10 Data Points
Indicator Data Points Actions
Number of Work-related Fatalities 1
Number of Fatalities as a Result of Work-related Injuries 8
Number of Fatalities of the Last 3 Years 1
B2.2 Lost Days Due to Work Injury
11 Data Points
Indicator Data Points Actions
Lost Time Injury Frequency Rate (LTIFR/LTIR) 2
Lost Days Due to Work-related Injuries 9

B3.1 The Percentage of Employees Trained
33 Data Points
Indicator Data Points Actions
Percentage of Employees Trained 6
Percentage of Trained Male Employees 6
Percentage of Trained Female Employees 6
Percentage of Trained Senior Management 6
Percentage of Trained Middle Management 6
Percentage of Trained General Employees 3
B3.2 Average Training Hours Completed per Employee
32 Data Points
Indicator Data Points Actions
Average Training Hours per Employee 7
Average Training Hours (Male) 6
Average Training Hours (Female) 6
Average Training Hours (Senior Management) 6
Average Training Hours (Middle Management) 6
Average Training Hours (General Staff) 1

B4.1 Avoid Child and Forced Labour
3 Data Points
Indicator Data Points Actions
Number of Violation Cases Related to Child Labour or Forced Labour 3

B5.1 Number of Suppliers by Geographical Region
10 Data Points
Indicator Data Points Actions
Number of Total Suppliers 5
Number of Suppliers in Mainland China 5

B6.3 Protection on Intellectual Property Rights
4 Data Points
Indicator Data Points Actions
Number of Patents Granted 2
Accumulative Number of Patents Granted 2

B7.1 Confirmed Incidents of Corruption
5 Data Points
Indicator Data Points Actions
Number of Concluded Corruption Lawsuits 5
B7.3 Anti-corruption Training
15 Data Points
Indicator Data Points Actions
Number of People Participated in Ethical Standards and Anti-corruption Training 5
Average Anti-corruption Training Hours for Directors and Management 5
Average Anti-corruption Training Hours for General Employees 5

B8.2 Resources Contributed to the Community
19 Data Points
Indicator Data Points Actions
Total Social Investment 1
Total Public Welfare Donations 4
Total Cash Donations 4
Total Volunteer Service Hours 5
Number of Employees Participating in Volunteer Activities 5

General
3 Data Points
Indicator Data Points Actions
Total Non-Hazardous Waste 2
Total Electricity Consumption 1

ESG Reports

Year Report Title Publication Date Raw KPIs Standard KPIs Processed Actions
2024 2024 Environmental, Social and Governance Report 2025-04-15 163 108 Yes
2023 2023 Environmental, Social and Governance Report 2024-04-16 234 168 Yes
2022 2022 Environmental, Social and Governance Report 2023-04-20 148 136 Yes
2021 2021 Environmental, Social and Governance Report 2022-04-28 68 69 Yes